Author: Emma Hein

India’s pharma ascension: 20% of global generic drugs, 40% of US generic approvals. But 70% API import dependence on China defines the next decade.

Healthcare cyber crisis: 500+ ransomware attacks in 2024. Change Healthcare paid $22M ransom. Five board-level priorities hospital leadership must address.

Longevity economy: $27B invested since 2020. Altos Labs, Retro Biosciences, Calico shaping the category. ARPA-H commits $2.5B.

Value-based care crosses 50% Medicare Advantage penetration. Five forces rewriting healthcare business models, payers, providers, employers.

AI drug discovery: $50B in Big Pharma partnerships since 2022. Insilico, Recursion, Isomorphic compressing pharma timelines from decade to 18 months.

GLP-1 disruption beyond pharma: 12M Americans on Ozempic. Five industries, food, insurance, healthcare, consumer goods, telehealth, reshaped.

Carbon markets are now a $2 trillion infrastructure layer. Compliance markets are setting prices that affect corporate decisions; voluntary markets are recovering with stronger methodology. For carbon-exposed businesses, engagement is no longer optional.

ESG investing has reached a more sustainable equilibrium after the boom and backlash. The marketing category has receded; the substantive integration of environmental and social factors into investment has continued. Understanding the difference matters.

Feeding 8 billion people while managing climate stress and water scarcity is the food system’s defining challenge. Which agricultural and food technologies are delivering real impact, and which are still promising but unproven.

Sustainable businesses are outperforming on revenue growth, margins, and capital costs. The green premium is real, measurable, and earned through operational substance, not communications strategy.